Antiretroviral treatment and travel to developing countries

Journal of Travel Medicine

Volumn 6, Issue 1, 1999, Pages 27-31

  Colebunders, Robert ^a   Nachega, Jean ^a   Van Gompel, Alfons ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; COMPLIANCE (PHYSICAL); DEVELOPING COUNTRY; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPPORTUNISTIC INFECTION; REVIEW; TRAVEL; TROPICS; VACCINATION; VIRUS LOAD;

EID: 0032826183     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.2310/7060.1999.00007     Document Type: Review

References (19)

1. Kemper CA, Linett A, Kane C, Deresinski SC. Frequency of travel of adults infected with HIV.J Travel Med 1995;2:85-88.
2. Kemper CA, Kane C, Griffiths D, et al. Motivation for travel and effect on health of HIV-infected persons. Third Conference on International Travel Medicine - Paris, 1993; Abstract 313:238.
3. Steffen R, Rickenbach M, Wilhelm U, et al. Health problems after travel to developing countries. J Infect Dis 1987; 156:84-90.
4. Steffen R, Lobel, OH. Travel medicine. In: Cook GC, ed. Manson's Tropical Diseases. 20th Ed. London: Saunders, 1996:407-420.
5. Wilson ME, Fordham Von Reyn C, Funberg HV. Infections in HIV-infected travelers: risks and prevention. Ann Intern Med 1991; 114:582-592.
6. Parenti DM. The international traveler and HIV infection. In: Travel Medicine Advisor, 1992; 10.1-10.13.
7. Van Gompel A, Kozarsky P, Colebunders R. Adult travelers with HIV infection. J Travel Med 1997; 4:136-143.
8. BHIVA Guidelines Co-ordinating Committee: British HIV assocation guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349:1086-1092.
9. Carpenter ChCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997; 277(24):1962-1969.
10. Larder BA. Viral resistance and the selection of antiretroviral combinations.J Acquir Immune Detic Syndr Hum Retroviral 1995; 10:S28-S33.
11. Styrt BA, Piazza-Hepp TD, Chikami GK. Clinical toxicity of antiretroviral nucleoside analogs. Antiviral Res 1996; 31:121-135.
12. Taburet AM, Singlas E. Drug interactions with antiviral drugs. Clin Pharniacol 1996; 30(5):385-401.
13. Miller V, Staszewski S, Boucher CAB, Phair JP. Clinical experience with non-nucleoside reverse transcriptase inhibitors. AIDS 1997; 11 (Suppl A):S157-S164.
14. Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996; 124:1086-1087.
15. Carr A, Cooper DA. HIV protease inhibitors. AIDS 1996; 10 (Suppl A):S151-S157.
16. Kempf D, Marsh K, Denissen J, et al. Co administration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450. III Conference on Retroviruses and Opportunistic Infections. Washington DC, January 1996; Abstract 143.
17. Colebunders R, Karita E, Taelman H, Mugyenyi P. Antiretroviral treatment in Africa. AIDS 1997; 11 (Suppl B):S107-S113.
18. Centers for Disease Control and Prevention. Clinical Update. Impact ot HIV protease inhibitors on the trearment of HIV-infected tuberculosis patients with rifampin. MMWR 1996; 45:921-925.
19. Mann JM, Tarantola DJ. AIDS in the World II. Global dimensions, social roots and responses. The Global AIDS Policy Coalition. New York: Oxford University Press, 1996.